Ignite Creation Date:
2024-05-06 @ 12:14 PM
Last Modification Date:
2024-10-26 @ 12:56 PM
Study NCT ID:
NCT03718117
Status:
COMPLETED
Last Update Posted:
2021-09-28
First Post:
2018-03-05
Brief Title:
Descriptive Observational Study ALK-2016-CPHG
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
CHARACTERISTICS OF ADULT PATIENTS TREATED WITH CRIZOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER NSCLC WITH ALK GENE REARRANGEMENT OR ROS1 GENE REARRANGEMENT IN GENERAL HOSPITALS
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ALK2016CPHG
Brief Summary:
Descriptive Observational Study
Characteristics Of ALK-positive and ROS1-positive Adults Patients Non-Small Cell Lung Cancer NSCLC Treated With Crizotinib Within General Hospitals
Characteristics Of ALK-positive and ROS1-positive Adults Patients Non-Small Cell Lung Cancer NSCLC Treated With Crizotinib Within General Hospitals
Detailed Description:
Describe the characteristics of patients treated with crizotinib Describe efficacy safety observance and QoL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ALK-2016-CPHG | OTHER | Alias Study Number | None |